Showing results (181-190 of 586) with videos related to

Sort By:
Pageof 59
European Heart Journal|July 6, 2006
Patients using statin treatment within 24 h after admission for ST-elevation acute coronary syndromes had lower mortality than non-users: a report from the first Euro Heart Survey on acute coronary syndromesTimo Lenderink, Eric Boersma, Anselm K Gitt, et al.
The American Journal of Cardiology|January 6, 2009
ST resolution 1 hour after fibrinolysis for prediction of myocardial infarct size: insights from ASSENT 3Per Johanson, Yuling Fu, Galen S Wagner, et al.
American Heart Journal|September 11, 2013
Documentation of study medication dispensing in a prospective large randomized clinical trial: experiences from the ARISTOTLE TrialJohn H Alexander, Elliott Levy, Jack Lawrence, et al.
Thrombosis Research|February 25, 2016
Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding eventsAmmar Majeed, Hun-Gyu Hwang, John W Eikelboom, et al.
Thrombosis and Haemostasis|January 29, 2016
D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudyAgneta Siegbahn, Jonas Oldgren, Ulrika Andersson, et al.
European Heart Journal|December 25, 2004
Quantitative T-wave analysis predicts 1 year prognosis and benefit from early invasive treatment in the FRISC II study populationMichael D Jacobsen, Galen S Wagner, Lene Holmvang, et al.
American Heart Journal|April 21, 2009
Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatranMichael D Ezekowitz, Stuart Connolly, Amit Parekh, et al.
Clinical Chemistry|December 23, 2006
Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assayTibor Kempf, Rüdiger Horn-Wichmann, Georg Brabant, et al.
European Heart Journal|May 10, 2011
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trialJonas Oldgren, Andrzej Budaj, Christopher B Granger, et al.
Plos One|November 14, 2023
Development and validation of a quantitative Proximity Extension Assay instrument with 21 proteins associated with cardiovascular risk (CVD-21)Agneta Siegbahn, Niclas Eriksson, Erika Assarsson, et al.
Pageof 59